We use essential cookies to run this site. Analytics & marketing cookies load only with your consent — see our Cookie Policy and Privacy Policy.

Industries

Pharma and life sciences — GxP, 21 CFR Part 11 and data-integrity security

Manufacturers, CROs and life-sciences firms must keep computerised systems validated and data-integrity intact under CDSCO and US FDA 21 CFR Part 11, while protecting patient and trial data under DPDP.

Applicable regulations

  • US FDA 21 CFR Part 11 and GxP data-integrity expectations
  • CDSCO requirements for computerised systems in regulated operations
  • DPDP Act 2023 for patient, trial and employee personal data
  • ISO 27001 ISMS and SOC 2 for enterprise and partner assurance

Common cybersecurity risks

  • Data-integrity failures in GxP computerised systems (ALCOA+)
  • Unvalidated changes to manufacturing and LIMS/QMS platforms
  • Exposure of clinical-trial and patient personal data
  • Insecure interfaces between IT, lab instruments and OT
  • IP theft of formulations and research data

Audit findings we typically see

  • Incomplete audit trails and access controls in GxP systems
  • Weak segregation between IT, lab and manufacturing networks
  • No DPDP-aligned handling of patient and trial data
  • Untested backup and recovery for validated systems
  • No incident-response process spanning quality and security

Services required

Our engagement approach

  • Discovery. Inventory GxP and enterprise systems, data flows and interfaces; confirm 21 CFR Part 11, CDSCO and DPDP obligations.
  • Assessment. Security testing and control-gap review mapped to data-integrity (ALCOA+), ISO 27001 and DPDP, without disrupting validated systems.
  • Remediation. A prioritised, validation-aware roadmap for access, audit-trail and segmentation fixes.
  • Assurance. Retest, audit-grade reporting and inspection-ready evidence.

Expected evidence

  • System and data-flow inventory across GxP and enterprise IT
  • Access-control and audit-trail review results
  • VAPT reports with closure evidence
  • DPDP and data-integrity control evidence

Indicative timeline

A typical assessment runs 6 to 12 weeks, depending on validated-system scope.

Deliverables

  • Gap assessment mapped to 21 CFR Part 11, ISO 27001 and DPDP
  • Validation-aware remediation roadmap
  • VAPT reports with closure evidence
  • Inspection-ready control evidence pack
Free tool
DPDP Readiness Checker
Check your readiness for India’s DPDP Act and see your priority gaps — free.
Try it free →
PCI SSC Qualified Security Assessor — CYBERSIGMA CONSULTING SERVICES LLP

QSA Authorised
CEMEA · Asia Pacific · USA

Ready to discuss your Pharma and life-sciences security requirement?

CERT-In empanelled · PCI QSA authorised — a senior consultant responds within 4 business hours. Free, no obligation.

Talk to an expert →Request a scope review

Delivering from Noida · Mumbai · Bengaluru · Pune · Dubai · Cairo · Melbourne — see all locations & addresses →